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Inhibition of Aβ42 aggregation using peptides selected from
combinatorial libraries
Michael Baine†, Daniel S. Georgie, Elelta Z. Shiferraw, Theresa P. T. Nguyen§, Luiza A.
Nogaj¶, and David A. Moffet*
Department of Chemistry and Biochemistry, Loyola Marymount University, One LMU Drive, Los
Angeles, CA 90045, USA

Abstract
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Increasing evidence suggests that the aggregation of the small peptide Aβ42 plays an important role
in the development of Alzheimer’s disease. Inhibiting the initial aggregation of Aβ42 may be an
effective treatment for preventing, or slowing, the onset of the disease. Using an in vivo screen based
on the enzyme EGFP, we have searched through two combinatorially diverse peptide libraries to
identify peptides capable of inhibiting Aβ42 aggregation. From this initial screen, three candidate
peptides were selected and characterized. ThT studies indicated that the selected peptides were
capable of inhibiting amyloid aggregation. Additional ThT studies showed that one of the selected
peptides was capable of disaggregating preformed Aβ42 fibers.
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Introduction
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Many proteins are known to adopt alternative misfolded structures that can be linked to a variety
of diseases [1–3]. These alternative structures no longer retain the function associated with the
native structure of the protein, and thereby become functionally useless or toxic to the cell.
Misfolded proteins are capable of aggregating together to yield a variety of oligomeric states,
ultimately forming fibers and amyloid plaque. The formation of fibers and amyloid in human
tissue appears to be a nearly irreversible reaction.
While resolubilizing amyloid appears to be very difficult to achieve, there has been some
success made in slowing the rate of aggregation, if not preventing aggregation altogether.
Several chaperon-like proteins, such as clusterin and HSP20, as well as several antibodies have
been shown to be capable of preventing amyloid formation [4–10]. Likewise, several small
molecules and peptides have been shown to slow the formation of amyloid [11–26]. Recently,
Sato et al. synthesized several peptides found to inhibit the aggregation of Aβ42 [27]. These
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peptides synthesized by Sato and coworkers were rationally designed to bind to, and inhibit
the aggregation of, Aβ42.
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The use of small peptides as aggregation-inhibiting agents could prove therapeutically useful
for a variety of diseases, including Alzheimer’s disease. Slowing the progress of drug discovery
for Alzheimer’s disease is the lack of an inexpensive and easily accessible screen. Most of the
screens that have been reported make use of synthetic Aβ42 [28,29]. The synthesis of Aβ42 is
time-intensive and prohibitively expensive for use in screens of peptide libraries. Additionally,
synthetic Aβ42 has an extremely high propensity to form homo-oligomeric complexes in
solution. These initial oligomers act as seeds to promote the formation of amyloid. Because of
the difficulty in removing the seed oligomers, screens aimed at finding compounds that prevent
the earliest stages of amyloid formation are likely to fail.
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Here, we describe an EGFP-based screen, developed by Hecht and coworkers [30–32], to select
for small peptides capable of inhibiting the aggregation of Aβ42. Two peptide libraries were
constructed to associate with, and prevent the aggregation of, Aβ42. In this screen, the peptide
Aβ42 was genetically fused to EGFP. When expressed in Escherichia coli, the Aβ42-EGFP
fusion protein produces virtually no green color or fluorescence due to the amyloidogenic
nature of Aβ42. Aggregation of Aβ42 precludes folding, and hence fluorescence, of the EGFP
reporter. However, when Aβ42 is prevented from aggregating, the fused EGFP is capable of
folding and fluorescing brightly. In this screen, combinatorially randomized peptides were coexpressed in E. coli with the Aβ42-EGFP fusion protein. Peptides that resisted cellular
degradation and prevented the aggregation of Aβ42 permitted EGFP to fold and fluoresce.
Therefore, individual E. coli colonies expressing both a library peptide and Aβ42-EGFP were
screened to select for those colonies that showed the greatest fluorescence.

Materials and Methods
Materials
Synthetic peptides were prepared by GenScript Corporation. DNA purification kits were from
Qiagen Inc. Klenow Fragment DNA polymerase and restriction enzymes were from New
England Biolabs. Expand High Fidelity DNA Polymerase was from Roche. pET 28a and
pCDF-1b plasmids were from Stratagene. DNA sequencing was performed by Davis
Sequencing.
Construction of the Aβ42 Gene
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The Aβ42 gene was constructed using polymerase chain reaction (PCR)-based gene assembly
[33]. Ten single-stranded DNA oligonucleotides (Table S1, Supporting information) were
designed to base-pair with their upstream and downstream pairing partners. Codons were
optimized for expression in E. coli. An oligo master mix was prepared by adding 2 µl of a 100
µM solution of each oligonucleotide to a single tube. To assemble the full-length Aβ42 gene, 1
µl of the oligo master mix was PCR amplified using Expand High Fidelity Polymerase (Roche).
Construction of p Aβ42-EGFP
The synthetic Aβ42 gene was doubly digested with HindIII and EcoRI and ligated into an
analogously digested p28EGFP plasmid that contains the gene for EGFP. [The EGFP gene,
and other similar fluorescent proteins, is commercially available from Clontech Laboratories,
Inc. The EGFP gene was PCR amplified using the primers 5′-GAA CTG GAC CAT ATG GTG
AGC AAG GGC GAG GAG-3′ and 5′-GTT ACG CTG GAA TTC TTA CTT GTA CAG CTC
GTC CAT GCC-3′ which produce an NdeI restriction site at the 5′ end of the gene and an
EcoRI site at the 3′ end of the gene. The PCR product was doubly digested with NdeI and
EcoRI restriction endonucleases (New England Biolabs) and ligated into an analogously
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digested pET28a plasmid (Novagen)]. The final construct, p28Aβ42-EGFP was verified with
DNA sequencing. In this construct, the Aβ42 peptide is genetically linked to EGFP through a
short flexible linker sequence. The Aβ42-EGFP gene was removed from the pET28a plasmid
using NcoI and HindIII restriction endonucleases and ligated into an analogously digested
pCDF-1b plasmid yielding pAβ42-EGFP.
Construction of the Peptide Libraries
Two peptide libraries were designed to match the suspected aggregation-prone regions of
Aβ42. Combinatorial variation was introduced to the libraries using degenerate codons (Table
S2, Supporting information). Library 1 was designed to associate with Aβ42 amino acids 29–
42 and Library 2 was designed to associate with Aβ42 amino acids 17–21 (Figure 1). The two
libraries were constructed using three synthetic DNA oligonucleotides (Table S2, Supporting
information), as described in the supplementary materials.
Screening Peptide Libraries
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The pAβ42-EGFP plasmid (Strepr) was cotransformed with either the Library 1 or the Library
2 plasmid library (Ampr) into electrocompetent BL21 (DE3) E. coli cells (Stratagene) using a
BTX ECM388 electroporator. The transformed colonies were plated on sterile nitrocellulose
discs on LB media plates that contained both ampicillin and streptomycin. The plates were
incubated for 15 h at 37 °C. The nitrocellulose discs, covered in individual colonies, were
transferred to LB media plates containing ampicillin, streptomycin, and 2 mM IPTG. These
plates were incubated at 37 °C for 3–6 h. Plates were scanned both visually and under 490 nm
wavelength light (Figure 2) to select green-colored fluorescent colonies.
Quantification of Cell Culture Fluorescence
Selected colonies were grown to an O.D.600 of 0.7 before protein induction with 1 mM IPTG.
The induced E. coli were incubated at 37 °C with shaking for 4 h. After 4 h, O.D.600 and
fluorescence emission (Ex490 nm and Em516 nm) of each culture was recorded. Only colonies
showing an increase in fluorescence compared with cultures expressing Aβ42-EGFP alone
were selected for further testing.
Preparing Disaggregated Aβ42
In 4.0 ml of HFIP, 0.5 mg synthetic Aβ42 (GenScript Corp) was dissolved and placed in a
sonicating water bath for 20 min. The solution was divided into 400 µl aliquots and stored at
−80 °C.
ThT Binding of Aβ42 in the Presence of Selected Peptide Inhibitors
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ThT binding studies were performed as described by LeVine [34]. Disaggregated Aβ42 (as
described above) was thawed and the HFIP removed over a stream of nitrogen gas. The
resulting solid Aβ42 was dissolved in PBS buffer to yield a 0.2 mg/ml stock solution. This
stock solution was divided evenly among tubes containing the selected peptides dissolved in
PBS buffer. The in-solution concentration of Aβ42 peptide was 40 µM for each sample and the
concentrations of selected peptides ranged from 1.2 mM to 20 µM. The samples containing
Aβ42 and selected peptides were incubated at 37 °C with shaking (120 rpm). At various time
points, 15 µl aliquots were removed and mixed with 485 µl of 3 µM ThT in 50 mM glycine buffer
pH8.5. The ThT mixture was incubated at room temperature in the dark for 15 min before
recording the ThT fluorescence spectrum (Ex450 nm) using a Hitatchi F-7000 fluorescence
spectrophotometer. ThT fluorescence (Em488 nm) in the presence of each peptide inhibitor was
taken as a percentage of the ThT fluorescence of Aβ42 alone.
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Monitoring the Disaggregation of Aβ42 with Selected Peptides
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For 24 h, 0.2 mg/ml stock Aβ42 (described above) was incubated at 37 °C with shaking (120
rpm) to promote formation of Aβ42 fibrils. This resulting solution was evenly divided among
tubes containing the peptide inhibitors at concentrations ranging from 10 µM to 1.2 mM. The
preformed Aβ42 fibrils with the peptide inhibitors were incubated at 37 °C with shaking (120
rpm). At 1, 3, 5 and 24 h, 15 µl aliquots were removed and added to 485 µl of 3 µM ThT in 50
mM glycine buffer pH 8.5. The ThT mixture was incubated at room temperature in the dark for
15 min before recording the ThT fluorescence spectrum (Ex450 nm) using a Hitatchi F-7000
fluorescence spectrophotometer.

Results and Discussion
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The 42-amino acid peptide, Aβ42, is highly amyloidogenic. The exact amino acids responsible
for the self-aggregation of Aβ42 are not known, but it is believed that the two hydrophobic
patches of Aβ42 may play a role. With that in mind, we constructed two peptide libraries
designed to anneal to either of the two hydrophobic patches of Aβ42 (Figure 1). The degenerate
peptide libraries were designed to maintain much of the hydrophobic character of the Aβ42
sequence. However, negatively charged aspartic acid residues were introduced into the
combinatorial mix to act as potential aggregation breakers. The goal was to produce a peptide
(or series of peptides) having a nonpolar face capable of annealing tightly to Aβ42, while
displaying a highly charged and polar aspartic acid residue that could sterically block additional
Aβ42 peptides from binding. The theoretical size of peptide Library 1 was 16 384 possible
sequence variants while that of Library 2 was 1600. The actual number of clones generated
was 55 000 for Library 1 and 35 000 for Library 2.
E. coli colonies co-expressing Aβ42-EGFP with library peptides were incubated on LB media
plates containing IPTG. Colonies were irradiated with 490 nm light to visually identify those
with the greatest amount of fluorescence emission at 516 nm (Figure 2). Six colonies were
initially selected based on their fluorescence emission intensity. Of the six colonies selected,
only three showed a substantially increased amount of fluorescence when grown in solution
(Figure S1, Supporting information). Two of these colonies were selected from Library 1
(named peptides 1A and 1B) and the third colony was selected from Library 2 (named peptide
2). The plasmid DNA from these clones was purified and sequenced to identify the selected
peptides (Table 1).
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With any screen, it is important to verify the activity of the selected candidates using additional
experimental tests. Candidates selected with this screen should be capable of inhibiting Aβ42
aggregation. However, this screen could unintentionally select for peptides that help EGFP to
fold and fluoresce without necessarily preventing Aβ42 aggregation. To directly test the ability
of the selected peptides to inhibit Aβ42 aggregation, the ThT fluorescence assay was used.
ThT fluorescence has been shown to be a useful indicator for detecting and quantifying amyloid
fibril formation [35,36]. ThT binds to the cross β-structure of amyloid proteins. The fluorescent
properties of ThT change when the dye moves from an aqueous environment, to the aggregated
amyloid protein. These fluorescent changes can be quantitated. As the concentration of amyloid
increases, so too does the ThT fluorescence. The three selected peptides were commercially
synthesized and dissolved in PBS buffer, pH 7.0. The aggregation time course of Aβ42 alone
and in the presence of each of the selected peptides (at 185 and 249 µM) is shown in Figure 3.
At 185 µM, peptide 1A shows modest ability to inhibit Aβ42 aggregation, while peptides 1B
and 2 show strong inhibitory potential. At 249 µM, all three selected peptides show considerable
inhibitory potential. Selected peptides incubated with ThT (in the absence of Aβ42) had the
same fluorescence properties as ThT alone in buffer (data not shown).
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While many substances have been shown to inhibit Aβ42 aggregation, few are known to
disaggregate preformed Aβ42 fibers. Peptides 1A, 1B, and 2 were tested using ThT for their
ability to disaggregate preformed Aβ42 fibers. Figure 4 shows the time course of Aβ42
disaggregation in the presence of peptide 2. While peptides 1A and 1B were found to inhibit
Aβ42 aggregation, they were not found capable of disaggregating preformed Aβ42 fibers.
However, peptide 2 was shown to inhibit Aβ42 aggregation as well as disaggregate preformed
Aβ42 fibers. Concentrations of peptide 2 as low as 400 µM were found to disaggregate
preformed Aβ42 (Figure 5) within 24 h. Peptide 2 is one of the few peptides we are aware of,
along with those of Sato et al. and Soto et al., shown to disaggregate preformed Aβ42 fibers
[26,27].

Conclusion
An Aβ42-EGFP construct was successfully used to select for peptides capable of inhibiting
the aggregation of Aβ42. This screen selected for peptides that could resist in vivo degradation
and inhibit Aβ42 aggregation. Two different peptide libraries, with a theoretical diversity of
nearly 18 000 different sequences, were screened. From this screen, three peptides were
ultimately selected for further investigation. ThT assays indicated that the selected peptides
were strong inhibitors of Aβ42 aggregation. Subsequent testing demonstrated that peptide 2 is
one of the few peptides known to disaggregate preformed Aβ42 fibers [26,27].
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Abbreviations used
EGFP

enhanced green fluorescent protein

ThT

Thioflavin T

HFIP

hexafluoroisopropanol

O.D.600

optical density at 600 nm

IPTG

Isopropyl β-D-1-thiogalactopyranoside

PBS

phosphate buffered saline, pH 7.0.

HSP20

Heat Shock Protein 20
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Figure 1.
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Amino acid sequence of Aβ42 compared to the degenerate amino acid sequences of Library 1
and Library 2 peptides. Combinatorial mixtures are indicated with amino acids shown in bold.
Underlined residues were conserved sequences designed to match Aβ42.
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Figure 2.

Colonies expressing both Aβ42-EGFP and library peptides are visualized under UV-light using
a Bio-Rad Molecular Imager VersaDoc MP Imaging System. Colonies with the greatest level
of fluorescence were selected for DNA sequencing and further in vitro tests. Note: The CCD
camera detector does not show data in color. Data are shown as fluorescence emission intensity.
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Figure 3.

Time course of Aβ42 aggregation as monitored with ThT binding in the presence of selected
peptides at (A) 185 and (B) 249 µM. Aβ42 was 40 µM for all samples. ThT fluorescence in the
presence of each peptide is shown as a percentage of the ThT fluorescence of Aβ42 alone at
each time point. The ThT fluorescence for Aβ42 alone increased for each time point. This
figure is available in colour online at www.interscience.wiley.com/journal/jpepsci.
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Figure 4.
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Disaggregation of preformed Aβ42 aggregates as monitored with ThT binding in the presence
of Peptide 2. Peptide 2 (1.2 mM) showed substantial ability to disaggregate preformed fibrils
(initial Aβ42 concentration was 40 µM). Data are the average of four separate trials conducted
on separate days. This figure is available in colour online at
www.interscience.wiley.com/journal/jpepsci.
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Figure 5.

ThT fluorescence of preformed Aβ42 fibrils (40 µM) with varying concentrations of peptide 2.
To promote aggregation, Aβ42 was incubated in PBS buffer for 24 h at 37 °C with vigorous
shaking. Peptide 2 was added, at varying concentrations, to the preformed fibers and incubated
for 24 h at 37 °C with vigorous shaking. After 24 h, the samples were tested with the ThT
binding assay. The raw data are shown. This figure is available in colour online at
www.interscience.wiley.com/journal/jpepsci.
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Table 1

Selected peptide sequences
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Peptide

Sequence

Peptide 1A

MSNKGASIGLMAGDVDIADSHS

Peptide 1B

MSNKGASNALMAGDGDIADSHS

Peptide 2

MQKLDVVAEDAGSNK

Peptides 1A, 1B, and 2 were selected for their ability to prevent Aβ42 aggregation as detected by an increase in Aβ42-EGFP fluorescence. Amino
acids that differ from wild-type Aβ42 are shown in bold.
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